No heart safety issues seen with Merck Januvia diabetes drug -study

June 8 (Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker's biggest product.